Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide

AAPS PharmSciTech

Volumn 1, Issue 1, 2000, Pages

  Demond, Wade ^a   Kenley, Richard A ^b   Italien, James L ^a   Lokensgard, David ^c   Weilersbacher, G ^b   Herman, Keith ^d  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b Cabrillo Facility of Magellan Laboratories Inc   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

^d WATERS CORPORATION   (United States)

Author keywords

Diastereoselectivity; Orthogonal separation; Peptide Analysis; Pramlintide; RP HPLC; SCX HPLC

Indexed keywords

ALANINE; CYSTEINE; LEUCINE; LYSINE; PRAMLINTIDE; TYROSINE; AMYLOID;

ACCURACY; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATION EXCHANGE; CONTROLLED STUDY; DEGRADATION KINETICS; DRUG FORMULATION; DRUG IMPURITY; DRUG PURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN DEPENDENT DIABETES MELLITUS; ISOMER; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; STEREOSPECIFICITY; CHEMISTRY; DRUG CONTAMINATION; ION EXCHANGE CHROMATOGRAPHY; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

AMYLOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; DRUG CONTAMINATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0006719851     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt010106     Document Type: Article

References (10)

1. Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325-331.
2. Young AA. Amylin regulation of fuel metabolism. J Cellular Biochem. 1994;55 (Supp):12-18.
3. Amiel S. Amylin and diabetes. Lancet. 1993; 341:1249-1250.
4. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45(Suppl 2):235A.
5. Ahern TJ, Manning MC, eds. Stability of Protein Pharmaceuticals. Part A. Chemical and Physical Pathways of Protein Degradation. New York, NY: Plenum Press; 1992.
6. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903-917.
7. Patel K, Borchardt RT. Chemical pathways of degradation III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res. 1990;7:787-793.
8. Capasso S, Mazzarella L, Zagari A. Deamidation via cyclic imide of asparaginyl peptides: dependence on salts, buffers, and organic solvents. Peptide Res. 1991;4:234-241.
9. Robinson AB, Scotchler JW, McKerrow JM. Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides. J Am Chem Soc. 1973;85:8156-8159.
10. Hekman C, Demond W, Dixit T, et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product. Pharm Res. 1998;15:650-659.